GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (FRA:04I) » Definitions » ROA %

InVivo Therapeutics Holdings (FRA:04I) ROA % : -94.97% (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is InVivo Therapeutics Holdings ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. InVivo Therapeutics Holdings's annualized Net Income for the quarter that ended in Sep. 2023 was €-10.11 Mil. InVivo Therapeutics Holdings's average Total Assets over the quarter that ended in Sep. 2023 was €10.64 Mil. Therefore, InVivo Therapeutics Holdings's annualized ROA % for the quarter that ended in Sep. 2023 was -94.97%.

The historical rank and industry rank for InVivo Therapeutics Holdings's ROA % or its related term are showing as below:

FRA:04I' s ROA % Range Over the Past 10 Years
Min: -233.77   Med: -97   Max: -45.31
Current: -65.92

During the past 13 years, InVivo Therapeutics Holdings's highest ROA % was -45.31%. The lowest was -233.77%. And the median was -97.00%.

FRA:04I's ROA % is ranked worse than
71.2% of 1552 companies
in the Biotechnology industry
Industry Median: -34.765 vs FRA:04I: -65.92

InVivo Therapeutics Holdings ROA % Historical Data

The historical data trend for InVivo Therapeutics Holdings's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings ROA % Chart

InVivo Therapeutics Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -146.95 -86.75 -56.50 -46.98 -53.48

InVivo Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.60 -57.05 -53.80 -53.12 -94.97

Competitive Comparison of InVivo Therapeutics Holdings's ROA %

For the Biotechnology subindustry, InVivo Therapeutics Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InVivo Therapeutics Holdings's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's ROA % distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's ROA % falls into.



InVivo Therapeutics Holdings ROA % Calculation

InVivo Therapeutics Holdings's annualized ROA % for the fiscal year that ended in Dec. 2022 is calculated as:

ROA %=Net Income (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=-9.903/( (19.266+17.768)/ 2 )
=-9.903/18.517
=-53.48 %

InVivo Therapeutics Holdings's annualized ROA % for the quarter that ended in Sep. 2023 is calculated as:

ROA %=Net Income (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=-10.108/( (12.307+8.98)/ 2 )
=-10.108/10.6435
=-94.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2023) net income data. ROA % is displayed in the 30-year financial page.


InVivo Therapeutics Holdings  (FRA:04I) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-10.108/10.6435
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-10.108 / 0)*(0 / 10.6435)
=Net Margin %*Asset Turnover
=N/A %*0
=-94.97 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


InVivo Therapeutics Holdings ROA % Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


InVivo Therapeutics Holdings (FRA:04I) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

InVivo Therapeutics Holdings (FRA:04I) Headlines

No Headlines